{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"}]}],"title":"New ITP medication, n=103"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Increase in dose of ITP med from baseline, n=103"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Platelet transfusion, n=103"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Splenectomy, n=103"}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"description":"Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy","groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"OG000","title":"Eltrombopag"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Number of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag.","type":"SECONDARY","unitOfMeasure":"Participants"}